2 insiders bought €1.6M of shares over the last 90 days, the latest filed 01 Sept 2026.
Every trade that managers of Lineage, Inc. disclose to SEC (Form 4) is tracked on this page. In the past year (18 October 2025 to 18 October 2026), 35 filings came from 17 insiders.
Not one open-market sale was filed. On the buying side, 5 insiders reported 9 purchases totalling €6.2M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 3 finance chiefs and 2 chief executives. Forste Adam Matthew Schwartz filed the largest purchase, €2.2M, on 12 November 2025.
With 35 filings in twelve months, the company is more active than the median of 19 filings across the 5,810 companies we follow on the same exchange. Over the whole record (from 2024), the tally stands at 19 purchases and no sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 5.36 bn USD and net income of -100.0 m USD, with a dividend of 2.11 USD per share.
The data flag 5 purchases as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 1 September 2026, 46 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Village Farms International, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate Lineage, Inc. Hold (neutral), based on 19 analysts. Average price target: US$43.79.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 76 declarations
Lineage, Inc. is a NASDAQ-listed company that specializes in developing innovative solutions for the biotechnology industry. It focuses on research and development of products that enhance health and well-being.
Purchases our model currently ranks for the recommendations list.
All recommendationsInsider filings
Over the last 90 days, 3 filings published between 10 August and 25 September 2026: 2 open-market purchases by insiders for €1.6M. 1 other filing (not open-market purchases or sales: grants, options, plans, sale notices, block transfers). Largest amounts: Marchetti Kevin Patrick (Co-Executive Chairman), purchases of €847k; LeMasters Robb A. (Chief Financial Officer), purchases of €717k.
Summary written automatically from public filings, without human review. General information, identical for every reader: it is not investment advice or a recommendation to buy or sell. Investing involves a risk of capital loss. Generated on 14 October 2026 (UTC)
| Fiscal year end | Revenue | Net income | Diluted EPS | Dividend per share | Filing |
|---|---|---|---|---|---|
| Dec 2025 | 5.36 bn USD | -100.0 m USD | -0.43 USD | 2.11 USD | 10-K |
| Dec 2024 | 5.34 bn USD | -664.0 m USD | -3.70 USD | 0.91 USD | 10-K |
| Dec 2023 | 5.34 bn USD | -77.0 m USD | -0.73 USD | 0.55 USD | 10-K |
| Dec 2022 | 4.93 bn USD | -63.0 m USD | -0.51 USD | n.d. | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.